Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Motor Activity 234Breast Neoplasms 132Neoplasms 97Prostatic Neoplasms 34Fatigue 34Obesity 24Lung Neoplasms 23Colorectal Neoplasms 22Polycystic Ovary Syndrome 17Ovarian Neoplasms 13Colonic Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Lymphoma 11Carcinoma, Non-Small-Cell Lung 11Weight Loss 10Rectal Neoplasms 10Multiple Myeloma 10Lymphedema 10Hematologic Neoplasms 10Head and Neck Neoplasms 10Leukemia 9Cardiotoxicity 9Insulin Resistance 8Brain Neoplasms 8Stomach Neoplasms 7Peripheral Nervous System Diseases 7Overweight 6Esophageal Neoplasms 6Cognitive Dysfunction 6

Interventions

Vincristine 1Saline Solution 1Radiotherapy 1Pemetrexed 1HhAntag691 1Gemcitabine 1Fentanyl 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Control Groups 1Cisplatin 1Central Venous Pressure 1Bupivacaine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infratentorial Neoplasms × Exercise × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡